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Purpose: The aim of this study was to evaluate the surgical outcomes of abdominal total gastrectomy, without mediastinal lymph node 
dissection for type II and III gastroesophageal junction (GEJ) cancers.
Materials and Methods: We retrospectively reviewed surgical outcomes in 67 consecutive patients with type II and III GEJ cancers that 
were treated by the surgical resection between 2004 and 2008. 
Results: Thirty (45%) patients had type II and 37 (55%) had type III tumor. Among the 65 (97%) patients with curative surgery, 21 
(31%) patients underwent the extended total gastrectomy with trans-hiatal distal esophageal resection, and in 44 (66%) patients, 
abdominal total gastrectomy alone was done. Palliative gastrectomy was performed in two patients due to the accompanying perito-
neal metastasis. The postoperative morbidity and mortality rates were 21.4% and 1.5%, respectively. After a median follow up of 36 
months, the overall 3-years was 68%, without any differences between the Siewert types or the operative approaches (transhiatal ap-
proach vs. abdominal approach alone). On the univariate analysis, the T stage, N stage and R0 resection were found to be associated 
with the survival, and multivariate analysis revealed that the N stage was a poor independent prognostic factor for survival.
Conclusions: Type II and III GEJ cancers may successfully be treated with the abdominal total gastrectomy, without mediastinal lymph 
node dissection in the Korean population.
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Introduction
Despite the decreasing global incidence of gastric cancer, the 
gastroesophageal junction (GEJ) cancers have greatly increased in 
the W estern countries.(1) However, distal gastric cancer is still a 
predominant type among gastric cancers in Korea and Japan(2,3) 
and patients are often diagnosed at an early stage with the use of 
endoscopy for mass screening.(4-6) Besides, the epidemiology of 
GEJ cancers is also quite different from that of the W est, in which 
type I GEJ cancer is extremely rare, while type II and III account 
for the types of the GEJ cancers in Korea. 
Although achieving complete tumor resection (R0 resection) is 
the mainstay of surgical treatment for GEJ cancers, the operative 
approaches, especially regarding the need for thoracotomy, still 
remain controversial.(7) Because of the frequent tumor infiltration, 
at least 6 cm of grossly normal esophageal resection has been ad-
vocated by several groups to achieve negative resection margins in 
the W est.(8-10) Some investigators have even insisted that as long 
as 10 cm of esophageal resection is required to minimize the risk 
of positive proximal margins.(11,12) To secure these long proximal 
resection margins, thoracotomy often should be performed along 
with abdominal total gastrectomy. Possible metastasis to the medi-Surgery for Cardia Cancers
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astinal lymph nodes is another concern necessitating thoracotomy 
in GEJ cancer. However, the relationship between the operative 
approaches and survival still remains to be investigated.
Although GEJ cancer are surgically treated as another entity 
of esophageal cancer in the W est, the surgical approach to GEJ 
cancers in Korea is just similar to that for gastric cancer, in which 
abdominal total gastrectomy without mediastinal lymph node dis-
section is commonly performed. To date, there were few case 
and study about the evaluation of the outcome of abdominal total 
gastrectomy in GEJ cancer in asia. In this study, we evaluated the 
surgical outcomes of abdominal total gastrectomy with the selective 
transhiatal approach that was perform for type II and III GEJ can-
cers to establish the optimal operative approach for these tumors 
and to define the prognostic factors. The aim of this study was to 
evaluate the short term and the long term results of the surgical 
procedure that was removal of complete tumor margin with the 
selective transhiatal approach or not.
Materials and Methods
1. Patients
From 2004 to 2008, 1775 patients underwent surgery for gastric 
carcinoma at our institution. By reviewing the operation record, 
pathological reports, and surgical specimen pictures, 67 (3.8%) pa-
tients with type II and III GEJ cancers and who were treated by 
surgical resection were included in this study. GEJ cancers were 
defined as tumors whose center was within 5 cm proximal and 
distal of the anatomical cardia, and were classified according to the 
Siewert’s classification of GEJ cancer.(13) 
All patients were preoperatively evaluated with endoscopy along 
with biopsy, abdominal computed tomography (CT) scanning, and 
a barium swallow study. Endoscopic ultrasound was performed in 
selected cases. None of the patients in this study received chemo-
therapy or radiation therapy before the operation. After operation, 
the patients were followed up every six months for the first three 
years, and then every 12 months after that. Disease recurrence was 
detected by physical examination, tumor markers, endoscopy and 
abdominal CT scanning. 
The data regarding the patient demographics, the operative 
procedures, the pathologic results and the short-term surgical out-
comes was obtained from a retrospective review of the medical 
records. The histologic differentiation and staging were principally 
based on the 6th edition of the International Union Against Can-
cer TNM classification for gastric carcinoma.(14) The information 
regarding disease recurrence and survival were obtained during 
outpatient clinical visits and by telephone interviews. 
2. Operative procedures
The choice of surgical approach was based on the goal of 
achieving complete macroscopic and microscopic tumor resection. 
In general, abdominal total gastrectomy was performed with resec-
tion of the distal esophagus with at least 3 cm of a gross surgical 
margin from the tumor. The transhiatal approach was performed 
in selected cases where complete resection was less likely to be 
achieved with the abdominal approach alone, based on the preop-
erative examinations or the intraoperative findings. Intraoperative 
frozen section analysis was performed in every operation, and the 
adequacy of the extent of esophageal resection was confirmed. 
For most patients, D2 lymph node dissection was performed as a 
standard procedure as is outlined by the principles of the Japanese 
Classification of Gastric Carcinoma.(15) And mediastinal lymph 
node dissection was not undertaken in this study.
The mode of reconstruction was mechanical esophagojejunos-
tomy or jejunal interposition, and the mode was selected according 
to the surgeon’s preference. 
3. Statistics
Statistical analysis was performed using the software SPSS ver-
sion 12.0 statistical package for windows (SPSS Inc., Chicago, IL, 
USA). Chi-square tests or Fisher’s exact tests and the student’s t-
test were used for comparisons as appropriate. Patient survival was 
calculated using the Kaplan-Meier method and the patient survival 
between groups was compared using the log rank test. Univariate 
and multivariate analysis were performed using the Cox regression 
models to identify the prognostic factors. A P-value ＜0.05 was 
considered statistically significant throughout the study. 
Results
The patients consisted of 48 men and 19 women with a mean 
age of 61.5±11.6 years. The tumor location described in the final 
pathologic report was based on Siewert classification, and this re-
vealed 30 type II and 37 type III tumors. No significant differences 
were observed between the type II and III tumors with respect to 
gender, Lauren’s classification, the N stage, and the presence of 
Barrett’s esophagus (Table 1). However, there were significant dif-
ferences in age, the histologic grade, the tumor size, and the T stage 
between the two groups: an older age, more histologic grade G1/2 Kim KT, et al.
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tumors, a smaller tumor size, and more pT1/2 stage tumors were 
the specific features of the type II tumors. 
With respect to lymph node metastasis, both tumor types 
showed similar patterns of lymphatic spread. For both types of tu-
mor, lymph nodes number 1, 2 and 3 were the most commonly in-
volved lymph nodes, with spreading toward the celiac lymph nodes 
(Fig. 1).
1. Surgical outcomes
Of the 67 patients, 65 (97.0%) patients underwent surgery with 
a curative intent, and two patients underwent palliative gastrectomy 
due to disseminated peritoneal metastasis. Twenty-two (33%) 
patients required the transhiatal approach for securing esophageal 
resection margin, while 45 (67%) patients required the abdominal 
approach only (Table 2). As a result, the transhiatal approach was 
Table 1. The clinicopathological features of the GEJ cancers 
Total (n=67) Type II (n=30) Type III (n=37) P-value
Age, years (±SD) 61.5±11.6 64.6±8.8 59.0±13.1 0.049
Gender (male : female) 48 : 19 23 : 7 25 : 12 0.411
Lauren classification 0.055
  Intestinal 43 (64.2) 23 (76.7) 20 (54.1)
  Diffuse 24 (35.8) 6 (23.3) 17 (45.9)
Histologic grade 0.042
  G 1-2 31 (46.3) 18 (60.0) 13 (35.1)
  G 3-4 36 (53.7) 12 (40.0) 24 (64.9)
Tumor size, cm (±SD) 5.1±2.4 4.1±2.8 5.8±2.2 0.003
Tumor depth  0.025
  pT1 14 (20.9) 11 (36.7) 3 (8.1)
  pT2 34 (50.7) 14 (46.7) 20 (54.1)
  pT3 16 (23.9) 4 (13.3) 12 (32.4)
  pT4 3 (4.5) 1 (3.3) 2 (5.4)
Lymph node metastasis  0.612
  pN0 35 (52.2) 15 (50.0) 20 (54.1)
  pN1 15 (22.4) 8 (26.7) 7 (18.9)
  pN2 10 (14.9) 3 (10.0) 7 (18.9)
  pN3 7 (10.4) 4 (13.3) 3 (8.1)
TNM stage 0.684
  I 30 (44.8) 16 (53.3) 14 (37.8)
  II 16 (23.9) 6 (20.0) 10 (27.0)
  III 11 (16.4) 4 (13.3) 7 (18.9)
  IV 10 (14.9) 4 (13.3) 6 (16.2)
The numbers in parenthesis are percentages. TNM stage is based on the sixth edition of UICC/AJCC TNM classification. GEJ = gastroesophageal 
junction; SD = standard deviation; UICC = International Union Against Cancer; AJCC = American Joint Committee on Cancer.
Fig. 1. Lymph node metastasis at each regional station in the patients 
with type II and III tumors. These two tumor types had similar patterns 
of lymphatic spread, with most commonly involving the lymph node 
station 1, 2, and 3 nodes and the spread was directed toward the celiac 
nodes.Surgery for Cardia Cancers
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performed for 19 (63%) of the 30 type II tumors and for 3 (8%) of 
the 37 type III tumors. The mean proximal margin length (cm) was 
2.26±0.74 (range: 1.0~4.0 cm), and none of the patients revealed 
residual tumor cells at the esophageal resection margin. Combined 
spleen or pancreas resection was performed in 24 (35.8%) patients. 
Sixty-four (95.5%) patients underwent lymphadenectomy of more 
than D2, and the mean number of harvested lymph nodes was 45±9. 
A total of 17 (25.4%) patients developed postoperative compli-
cations with one in-hospital death. The most common complica-
tion was pancreatic fistula (n=5) and this was followed by abdomi-
nal infection (n=4), and surgical wound infection (n=2). The mean 
hospital stay (in days) was 16±3. 
2. Survival and the prognostic factors
With a median follow-up of 36 months (range: 13 to 58 
months), the overall survival rate at 3 years was 68%: it was 70% 
for patients with type II tumors versus 67% for the patients with 
type III tumors (P=0.546), and 72% for the transhiatal approach 
vs. 66% for the abdominal approach alone (P=0.811). A total of 14 
patients developed recurrence during the follow up: there were 11 
cases of peritoneal seeding, 3 cases of distant lymph node metasta-
ses, 2 cases of hematogenous metastases and 4 cases of locoregional 
recurrences. No patients had recurrence at the mediastinal lymph 
nodes during the follow-up. Meanwhile, no significant difference 
of the recurrence pattern was observed according to the Siewert 
types or the surgical approaches.
On the univariate analysis, the T stage (T1-2 vs. T3-4), N stage 
(N0 vs. N+) and R0 resection were significantly associated with 
survival, while the Siewert type or the transhiatal approach was not. 
Multivariate analysis of the significant variables on the univariate 
analysis showed that lymph node metastasis (hazard ratio=11.97, 
95% confidence interval=2.657~63.98) was an independent factor 
for a poor prognosis (Table 3).
Discussion
Adenocarcinomas of the GEJ are biologically aggressive and 
they are typically diagnosed at an advanced stage of disease pro-
Table 2. The surgical outcomes
Total (n=67) Type II (n=30) Type III (n=37) P-value
Curability 0.724
  R0 resection 65 (97.0) 29 (96.7) 36 (97.3)
  Non-R0 resection 2 (3.0) 1 (3.3) 1 (2.7)
Surgical approach <0.001
  Total gastrectomy only 45 (67.2) 11 (36.7) 33 (91.7)
  Combined trans-hiatal approach 22 (32.8) 19 (63.3) 3 (8.3)
Lymph node dissection 0.583
  D2 or more 64 (95.5) 28 (93.3) 36 (97.3)
  Less than D2 3 (4.5) 2 (6.7) 1 (2.7)
Reconstruction 1.000
  Jejunal interposition 11 (16.4) 4 (13.3) 6 (16.2)
  Esophagojejunostomy 56 (83.6) 26 (86.7) 31 (83.8)
Combined resection 24 (35.8) 7 (23.3) 17 (45.9) 0.096
  Spleen 12 4 8
  Distal pancreas 11 2 9
  Others 1 1 0
Proximal margin (cm, ±SD) 2.26±0.74 2.10±0.64 2.38±0.80 0.120
Retrieved lymph nodes (±SD) 45±9 44±14 46±22 0.637
Hospital stay (d, ±SD) 16±3 15±4 16±5 0.438
Morbidity 17 (25.4) 10 (33.3) 7 (18.9) 0.178
Mortality 1 (1.5) 1 (3.3) 0 0.448
The numbers in parenthesis are percentages. SD = standard deviation.Kim KT, et al.
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gression. As a result, they are difficult to treat and the patient prog-
nosis is poor even after curative surgical resection. The five-year 
survival rate after surgical resection has been reported to range only 
16% to 32.3%.(11,16,17) Although such reports are rare, the GEJ 
cancers in East Asia show significant differences of their clinico-
pathological features as compared with those observed in the W est. 
First, its incidence is very low despite of the high prevalence of 
gastric cancer. Second, distal esophageal adenocarcinomas related 
to Barrett’s mucosa (type I GEJ cancer) are rarely seen, and most 
GEJ cancers arise in the gastric cardia or subcardial region. Third, 
patients in these areas are often diagnosed at an early stage of disease 
because of the widespread use of endoscopy screening.(4-6) Thus, 
considering these distinctive features, abdominal total gastrectomy 
is frequently performed for GEJ cancers in Korea, rather than tho-
raco-abdominal approach in the W est, but only a few studies have 
reported surgical outcomes of this procedure. This study shows that 
abdominal total gastrectomy with selective trans-hiatal approach 
is appropriate in terms of securing safe proximal resection margin 
and acceptable postoperative morbidity. Besides, long term out-
comes were also similar to the historical controls. 
Achieving complete tumor resection is the mainstay of the sur-
gical treatment for GEJ cancers. The surgical approaches to achieve 
R0 resection for these tumors vary widely from esophagectomy 
through the transthoracic or transmediastinal approach to extended 
total gastrectomy with transhiatal resection.(18) Because of the 
frequent tumor infiltration at the esophageal resection margin, ex-
tended esophageal resection has been advocated by several research 
groups. Ito et al.(9) recommended that the surgical approach should 
be directed based on the goal of obtaining at least 6 cm of a gross 
proximal resection margin to avoid residual cancer cells at the re-
section margin, and this was generally consistent with that reported 
by Barbour et al.,(19) Bezzetti et al.,(8) and Mattioli et al.(10) How-
ever, most series have not demonstrated a survival benefit for one 
operative approach over another,(20,21) and proximal resection 
margin infiltration does not universally translate to poor survival 
when performing curative resection.(22)
In general, it has been well accepted that the selection of the 
surgical approach to GEJ cancers should be tailored based upon 
achieving macroscopic and microscopic tumor resection.(23) In 
this study, with performing grossly normal esophageal resection 
of only 3 cm, complete (R0) tumor resection was performed in 
as many as 97% of the patients. The rate of R0 resection of this 
study was considerably higher than those studies in the W est that 
reported a 55% to 75% rate of complete resection.(9,19,24) Unlike 
the strong correlation of a positive resection margin with the ex-
tent of the surgical resection as observed by Mattioli et al.,(10) our 
study found no difference in R0 resection between the abdominal 
approach and the transhiatal approach. Complete tumor resection 
was accomplished via the abdominal approach alone in 43 (64%) 
patients, and the transhiatal approach was required only in 22 (33%) 
patients. Microscopic mural extension of cancer cells was very rare 
in our experience, as reflected by the fact that no positive resection 
margin was observed for all patients who underwent surgery with 
a curative intent. Therefore, our study suggests that the required 
extent of esophageal resection for GEJ cancers in Korea may differ 
from those insisted in the W est, and the surgical approach could 
Table 3. The prognostic factors on the univariate and multivariate analysis
Variables
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Age (≤65 yr vs. >65 yr) 0.593 (0.233~1.511) 0.274
Gender (male vs. female)  1.243 (0.472~3.273) 0.660
Siewert type (type 2 vs. 3) 1.325 (0.631~3.305) 0.547
T stage (T1-2 vs. 3-4) 3.853 (1.549~9.584) 0.004 2.377 (0.895~6.317) 0.082
N stage (N- vs. N+) 14.731 (3.368~64.434) < 0.001 11.97 (2.657~53.98) 0.001
Curability (R0 vs. R1-2) 6.058 (1.726~21.264) 0.005 1.776 (0.476~6.621) 0.393
Lauren classification (intestinal vs. non-intestinal) 1.137 (0.447~2.889) 0.788
Surgical approach (TG vs. TG+THA) 1.072 (0.834~1.329) 0.543
Histologic grade (G1-2 vs. G3-4) 1.546 (0.620~3.855) 0.349
Tumor size 1.190 (0.993~1.426) 0.060
HR = hazard ration; CI = confidence interval; TG = total gastrectomy; THA = transhiatal approach.Surgery for Cardia Cancers
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be tailored using a less extensive esophageal resection, such as the 
selective use of the transhiatal approach based on abdominal total 
gastrectomy.
The application of less extensive esophageal resection and the 
resulting high R0 resection rate in this study may be explained that 
the distinctive surgical epidemiology of GEJ cancers in Korea is 
different from those observed in the W est.  It is well known that 
the degree of mural extension is strongly correlated with the T 
stage.(12,25) In W estern countries, most patients with GEJ cancers 
are typically diagnosed at an advanced stage as having T3 or T4 
tumors, and lymph node metastasis.(18,19) On the contrary, our 
study found over 70% of the patients had tumors limited within 
the serosal layer (T1 or T2), and nearly 50% of the patients had no 
lymph node metastasis. Controversy continues concerning the opti-
mal lymph node dissection when we perform GEJ cancer surgery. 
de Manzoni et al.(16)’s study suggested to perform total Gastrec-
tomy with D2 lymphadenectomy with advanced cardia cancer type 
II or III. Pedrazzani et al.(26)’s study said that chest nodal involve-
ment rate was 46.2% in type I, 29.5% in type II, 9.3% for type III. 
Siewert et al.(18)’s study suggested that lower mediastinal nodal 
involvement rate was 12% in type II, 5% in type III. So, our study 
performed D2 lymphadenectomy without mediastinal node dissec-
tion. Moreover, most GEJ cancers in our experience were limited 
in the cardia or subcardial region, which means that the vast ma-
jority of these tumors must be considered as gastric in origin and 
they should be treated as such. These characteristics of GEJ cancer 
observed in our study are consistent with those of other domes-
tic reports from Korea.(4,6) However, further studies with a large 
number of patients are needed to ascertain the surgical epidemiol-
ogy of GEJ cancers in Korea, and the optimal surgical approach 
should be determined based on these result.
In conclusion, our experience has shown that complete tumor 
resection can be achieved with less extensive esophageal resec-
tion as compared to those performed in the W est. To achieve R0 
resection, abdominal total gastrectomy with the selective use of 
the transhiatal approach was appropriate for treating GEJ cancer 
in Korea. This may be because the biologic and clinical features 
of GEJ cancer in Korea are different from those of the W est, yet 
further studies with a large number of patients will be needed to 
establish the proper surgical approach to GEJ cancer in Korea. 
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